



Record Quarter in growth and profits

Q1 financial results



Robert Wessman, President & CEO
Mark Keatley, CFO
Sigurdur Olafsson, President of N-America Sales



Forward looking statement


Any statement contained in this presentation that refers to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors. Actavis does not undertake the obligation to update or alter these forward-looking statements beyond its duties as an issuer of listed securities on the Iceland Stock Exchange.



Today's speakers



Robert Wessman
President & CEO



Mark Keatley
Executive CFO



Sigurdur O Olafsson
President of N-America Sales



Agenda

1. First quarter highlights
2. Financial highlights
3. Sales performance
 - Own-label
 - CEE Asia and WEMEA
 - North America
 - Third-party sales
4. Q&A





Quarterly highlights

- Revenue growth in all business divisions
- Net profit EUR31.3 million
- Underlying growth 23%
- Record number of product launches
- Integration activities on above expectations
- Acquisition of Sindan in Romania



Integration on track

- Strategic acquisitions 2005-2006
 - Lotus Laboratories, Biovena, Pharma Avalanche, Amide, Keri Pharma, Higia, Alpharma's Human Generics Business, Ophtha, Sindan
- Integration exceeding expectations
- Synergy targets and integration plan on track
 - Profitability enhanced
 - Structural changes made
 - Internal branding completed
 - Sales increased
 - Pipeline enhanced
 - Record number of product launches
 - Headcount right sized
 - Negotiations with key vendors



Acquisition of Sindan Compelling strategic rationale

- Dedication and expertise in the oncology field
 - New therapeutic area for Actavis
 - Opportunity to register and sell oncology product in Actavis markets
- Platform to sell current Actavis products in Romania
 - One of the fastest growing markets
 - Largest hospital supplier in Romania and few competitors in the international markets
- Strong growth potential
 - Fast growing Romania market
 - Export of Oncology products
- Highly profitable business model and sound balance sheet



Update on proposed offer for Pliva

Highly compelling strategic rationale

- Creates the third largest company in the global generics industry, with a leading position in key markets
- Product portfolio would cover the complete generics platform
- Access to strong biogenerics capabilities
- Allows increased access to low cost manufacturing facilities, more efficient distribution and enhanced supply chain capabilities
- Further expands Actavis' long term growth prospects

Proposal

- All cash offer of HRK630 per share, values PLIVA at US\$1.9 billion
- Management highly confident to finance the transaction through JP Morgan and HSBC

Latest Developments

- Discussions now in progress and NDA signed with PLIVA
- Actavis prepared to seek opportunities elsewhere if necessary



Record quarter in profits Exceeding management expectations


Thousands of Euro	Three months ended 31 March		
	Q1 2006	Q1 2005	% Change
Total revenues.....	341.879	101.790	235,9%
EBITDA.....	72.499	24.565	195,1%
EBITDA %.....	21,2%	24,1%	(2,9%)
Net profit (excl. minorities).....	31.859	11.095	187,2%

- Strong performance from all key revenue divisions with 23% underlying growth*
- First time contribution of Alpharma's Human Generics business
- 86 market and products launches in Group's markets
- EBITDA margin and profits exceeding management expectations
 - Underlying EBITDA growth of 17%
 - 58% increase in earnings per share (fully diluted)

* 20% at constant exchange rates



Well placed in key markets



Financial highlights



Mark Keatley
CFO




Financial highlights Q1

Thousands of Euro	Q1 2006	Q1 2005	% Change
Total revenues.....	341,879	101,790	235.9%
Total expenses.....	(291,836)	(82,918)	252.0%
EBITDA.....	72,499	24,565	195.1%
EBITDA/revenues.....	21.2%	24.1%	(2.9%)
EBIT.....	50,041	18,872	165.2%
Profit before tax (PBT).....	40,090	11,674	243.4%
Net profit*.....	31,859	11,095	187.2%
Underlying Growth.....	23.0%	21.9%	N/A
Earnings per share (EPS).....	0.00589	0.00372	58.4%


*Net Profit excluding Minority Interest

Revenue by quarter




Q1 Underlying growth 23%

Revenue Bridge




Financial highlights Q1

Q1 2005 Revenue by segments Q1 2006




API: Active Pharmaceutical Ingredients
Other: Revenues from Lotus, India

Gross Margin Bridge



EBITDA margin


EUR million




	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q1 2006
EBITDA	24.6	23.4	48.3	54.3	72.5
EBITDA to Revenues	24%	19%	30%	30%	21%

EBITDA Bridge

Q1 2005 to 2006 EBITDA Bridge




Cost ratio trend




Period	Cost of Sales	Sales & Marketing	General	R&D*	Total
2Q 2005	63.1	20.7	12.1	9.5	105.4
3Q 2005	72.9	22.2	14.9	14.4	124.4
4Q 2005	79.7	21.5	22.2	19.3	142.8
1Q 2006	186.2	51.0	32.1	22.6	291.8

*Expensed R&D

Balance sheet Assets



Balance sheet Equity & liabilities



	31/3 2006	31/12 2005
Stockholders' equity	1,015.2	997.3
Minority interest	11.0	10.7
Non-current liabilities	1,043.7	999.7
Current liabilities	520.6	386.9
Total Shareholder's Equity	2,590.5	2,394.6

Cash Flow EUR '000

	Jan- Mar 2006	Jan - Mar 2005
Working capital from operating activities	52,141	24,759
Net Cash provided by operating activities	(4,686)	24,755
R&D.....	(12,313)	(4,497)
CAPEX.....	(20,233)	(15,542)
Acquisitions.....	(147,683)	0
Other investments.....	0	(21,227)
Investing activities total.....	(180,229)	(41,266)
Changes in Capital Stock.....	14,440	0
Increase in debt (net).....	212,845	26,359
Other.....	0	0
Financing activities total	227,285	26,359
Net change in cash and cash equivalents	42,370	9,848
Effect of foreign exchange adjustments.....	(1,465)	471
Cash and cash equivalents at beginning of period.....	99,308	17,325
Cash and cash equivalents at end of period	140,213	27,644

Financial guidance

Guidance for 2006

- Expected revenue 2006 EUR1.36 billion
- EBITDA margin of 20.1
- Strong growth expected in North America and CEEA divisions
- Third-party division delivering low single digit growth

Sales performance


Sigurdur Oli Olafsson
President of North-America sales



Actavis Group sales - 1Q



Regional sales Q1




Other: Lotus, intellectual property and royalties

CEE sales



CEE Sales by Market 116.5 million in Q1 2006





CEE Highlights Q1 2006

EUR116.5 million

Highlights


- First quarter sales of the division grew by 62%
- 30 products were launched into key markets
 - Total of 24 different molecules/products
 - Five first to market



CEE - key markets


Turkey - 31% of division sales

- Sales grew by 30% to EUR 36.3 from Q1 2005
- Good volume growth on most products



Russia, Ukraine & CIS - 12% of division sales


- Strong growth of 11.5% up to EUR13.5 million
- Increased promotion and branding activity
- Three new products launched



CEE - key markets


Bulgaria - 17% of division sales

- Lower sales than anticipated in the quarter
- Stock level reduced at wholesalers




Balkan - 12% of division sales

- Good growth of 22% from 1Q 2005
- New markets like Romania, Albania and Republic of Srpska doing well




CEE sales Top five products

Total EUR116.5 million in Q1 2006




WEMEA sales



WEMEA Sales by Market

EUR71.9 million in Q1 2006



WEMEA Highlights Q1 2006


EUR71.9 million

Highlights

- Total sales of EUR71.9 million,
 - 95% has been generated as the result of the Alpharma acquisitions
- 25 products were launched
 - Total of 16 different molecules/products
 - 11 first to market

WEMEA - Q1 2006

Top 10 products



Third-party sales



Third-party sales by quarters - highlights

	Q1 2006
Sales	38.9
% of Group Revenues	11.4%
Underlying Growth	38.0%


Highlights

- Good increase from Q1 2005
- Sales performance of products in line with expectations
- 25 New market launches in Q1, thereof three on patent expiry
- Sales of intellectual property below expectations

Third-party sales - Q1 2006

Total EUR38.9 million


Sales by segments



Intellectual Property

- 2.4 million, down 23% from Q1 2005
- Revenue from 36 products

Sales by therapeutic class




Finished products

- 36.5 million, up 54% from Q1 2005
- Revenue from 39 products

Well placed in key markets - Q1

Finished products total EUR38.9 million




*Market split excludes sales of intellectual property

Third-party - Q1 2006 Top 10 products

Total EUR38.9 million

EUR million



North America sales



North America Sales EUR113.0 million


North America sales

	Q1 2006
Amide.....	35,993
Elizabeth.....	47,794
Semi Solid and liquids	29,226
Total.....	113,013

Highlights

- Strong performance of Amide
- Six new products launched in the quarter

Significant launch activity in Q1



A total of 86 product launches
A total of 47 different compounds/molecules
29 from Actavis R&D
18 from in-licensing



Development Status

	EU	US	ROW	Total
Development Projects	123	109	21	253
Molecules/Products	82	97	13	192
Ongoing Registrations				44



Total pipeline: 297 projects



Investor & Media Relations:

Robert Wessman, President & CEO Tel: +354 535 2300
Mark Keatley, CFO Tel: +354 535 2300
Halldor Kristmannsson Vice President Tel : +354 535 2300/
Corporate Communications +354 840 3425
Financial Dynamics - New York
Charles Armitstead Tel: (+1) 212 850 5600

